8月8日，步长制药（603858）发布公告称，其控股子公司四川泸州步长生物制药有限公司与菲律宾 GOODFELLOW PHARMACORPORATION 签署《独家供应协议》。 协议显示，GOODFELLOW 将在菲律宾区域独家代理注射用 Efparepoetin alfa 的注册、临床试验、推 广、分销及销售工作。泸州步长将提供注册申报所需的英文资料、技术支持以及必要的临床研究样品， 协助完成注册与试验过程；同时承担从中国运送至马尼拉的运输与保险事宜。GOODFELLOW 则负责 将注册材料翻译成当地语言，承担相关费用，并完成进口清关和税费缴纳。协议自进口药品许可证获批 之日起有效期五年，若履约情况良好可续约五年，相关知识产权均归泸州步长所有。 这一合作意味着泸州步长将以更快的速度进入菲律宾市场，并以此为起点辐射东南亚地区。对于步长制 药来说，这不仅是单个产品的国际化，更是生物药板块走向全球的重要一环，更是对中国医药企业"走 出去"大背景的积极响应。 02 创新驱动下的多元化发展战略 步长制药近年来围绕"创新驱动、多元化发展"核心战略，不断强化生物药板块。公司在巩固中药龙头地 位的同时，向生物药和化药领域倾 ...

Group 1 - Xinda Biologics reported a total product revenue exceeding 5.2 billion yuan in the first half of 2025, achieving a strong growth of over 35% year-on-year, driven by both oncology and comprehensive pipeline [1] - Eli Lilly's orforglipron demonstrated significant weight loss results in the ATTAIN-1 clinical trial, with the highest dose group (36 mg) achieving an average weight reduction of 12.4 kg, enhancing market confidence in the company's weight loss portfolio [1] Group 2 - AstraZeneca's Fasenra received approval for a new indication in China for the maintenance treatment of severe eosinophilic asthma in children aged 6 to <12 years, further solidifying its market position in respiratory diseases [2] Group 3 - Gan & Lee Pharmaceuticals reported a 57.18% increase in revenue to 2.067 billion yuan and a 101.96% increase in net profit to 604 million yuan in the first half of 2025, indicating strong business growth and enhanced profitability [3] Group 4 - Buchang Pharma announced an exclusive supply agreement with GOODFELLOW in the Philippines for the new biological drug Efparepoetin alfa, marking a significant step in the company's internationalization strategy and enhancing its brand value [4]